1646MO Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma

Anaplastic thyroid carcinoma (ATC) patients without a BRAF mutation have a dismal prognosis despite extensive multimodal therapy. In a retrospective analysis we have previously shown the combination of lenvatinib/pembrolizumab to be effective for ATC/PDTC patients with elevated PD-L1 expression or high mutation frequency. Within the ATLEP trial, we therefore prospectively investigated the effect of the lenvatinib/pembrolizumab combination in ATC and PDTC patients.